Last reviewed · How we verify
reduction of stroke and systemic embolism risk in non valvular af
Approved treatments
Clinical guidelines
- FDA label — 1L
Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. - FDA label — 2L
Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. - FDA label — 2L
Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- reduction of stroke and systemic embolism risk in non valvular af patent landscape — cliff calendar, originator estates, attackable patents
- reduction of stroke and systemic embolism risk in non valvular af treatment landscape brief
- reduction of stroke and systemic embolism risk in non valvular af treatment updates RSS
Frequently asked questions about reduction of stroke and systemic embolism risk in non valvular af
What are the treatment guidelines for reduction of stroke and systemic embolism risk in non valvular af?
FDA label publishes guidelines for reduction of stroke and systemic embolism risk in non valvular af. 3 guideline references tracked.
Related
- Treatment landscape: reduction of stroke and systemic embolism risk in non valvular af patent cliff · reduction of stroke and systemic embolism risk in non valvular af CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing